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ABSTRACT
The rate of DNA supercoil removal by human
topoisomerase IB (TopIB) is slowed down by the
presence of the camptothecin class of antitumor
drugs. By preventing religation, these drugs also
prolong the lifetime of the covalent TopIB–DNA
complex. Here, we use magnetic tweezers to
measure the rate of supercoil removal by drug-
bound TopIB at a single DNA sequence in real time.
This is accomplished by covalently linking camp-
tothecins to a triple helix-forming oligonucleotide
that binds at one location on the DNA molecule
monitored. Surprisingly, we find that the DNA
dynamics with the TopIB–drug interaction restricted
to a single DNA sequence are indistinguishable from
the dynamics observed when the TopIB–drug inter-
action takes place at multiple sites. Specifically, the
DNA sequence does not affect the instantaneous
supercoil removal rate or the degree to which
camptothecins increase the lifetime of the covalent
complex. Our data suggest that sequence-
dependent dynamics need not to be taken into
account in efforts to develop novel camptothecins.
INTRODUCTION
Eukaryotic Topoisomerase I (TopIB) is an enzyme that
allows for the removal of torsional stress from double-
stranded (ds)DNA molecules (1–4). It has been proposed
that TopIB acts in vivo as a swivelase ahead of a
replication fork to remove positive supercoils (5). TopIB
functions as a monomer and circumscribes the DNA
duplex (6,7), after which the active-site tyrosine attacks
the scissile phosphodiester of one of the strands of the
DNA duplex, generating a DNA-(30-phosphotyrosyl)-
enzyme intermediate, as well as a free 50-OH DNA end.
The torsional energy that is stored in supercoiled DNA
will then power rotation of the 50-OH end about the intact
strand and consequently, supercoils are removed through
a swivel mechanism that is termed ‘hindered’, in reference
to the signiﬁcant interactions between the spinning DNA
and the enzyme’s central cavity (8–10). Religation of the
DNA, which arrests the swivelling and thus terminates
supercoil removal, appears to be a stochastic process, as
the number of supercoils that are removed from the DNA
prior to religation follows an exponential distribution (8).
Although the transient covalent DNA-enzyme inter-
mediate nulliﬁes the requirement for an external energy
source fueling supercoil removal, the establishment of the
DNA-linked TopIB does constitute a risky catalytic route
that would pose a danger to the cell if the religation
reaction were prohibited. Small planar molecules, such as
the camptothecin class of antitumor drugs, can inhibit
religation and indeed are cytotoxic. They do so by
entering the nick that is created by TopIB and mimicking
a DNA base pair, locally deforming the DNA duplex in
the process (11–16). Binding of the drug results in a vast
decrease in the rate of religation and thus in an increase in
the time the covalent complex remains trapped on the
DNA (17–21). The generally held paradigm for drug-
induced cytotoxicity is that the advancing replication
machinery ‘collides’ with the trapped TopIB–CPT–DNA
ternary complex, giving rise to lethal DNA lesions and
fork collapse (12,14,22,23). However, a combination of
single-molecule and yeast-based experiments has recently
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toxicity, namely that upon treatment with camptothecin,
positive supercoils accumulate in a cell cycle-independent
manner, presumably owing to a preferential slow-down of
drug-mediated positive supercoil relaxation (19).
The DNA sequence at which cleavage by human TopIB
occurs is only mildly speciﬁc (2) and the drug-induced
stabilization of the covalent complex occurs at a subset of
these sites (12,24). Still, for all practical purposes, the
cleavage by TopIB can be considered independent of
DNA sequence (25). Indeed, drug treatment leads to
widespread DNA damage in cells that aﬀects a multitude
of genes, whether speciﬁc to cancer cells or not (14,24).
One strategy to improve the overall eﬃcacy of the
camptothecins is to render them DNA sequence-speciﬁc,
so as to inﬂict damage onto oncogenes in cancer cells (26).
An implementation of this strategy is the use of triple
helix-forming oligonucleotides (TFOs) conjugated to CPT
or topotecan (TPT) (27,28). A TPT molecule conjugated
to a triple helix bound in the DNA duplex is schematically
shown in Figure 1a. These constructs have previously been
shown to direct the drug-stabilized covalent complex to
speciﬁc sequences both in vitro and in cells (29).
Here, we make use of the ability to conjugate molecules
of the camptothecin class to a TFO to directly probe the
dynamical interactions between these antitumor drugs and
TopIB at a single DNA sequence using single-molecule
techniques. This use of TFO–CPT conjugates allows us to
study the uncoiling process under well-deﬁned conditions,
i.e. at a predeﬁned site on the DNA, with the expectation
that the underlying physics on the slow uncoiling could be
most eﬀectively studied. Speciﬁcally, we measure the
instantaneous uncoiling rate in the presence of drugs
and the lifetime of the drug-stabilized covalent complex.
By comparing these quantities to experiments performed
with free TPT in solution, i.e. to sequence-independent
uncoiling, we probe the eﬀect of sequence on drug-
mediated and TopIB-catalyzed supercoil removal.
A previous single-molecule study (19) showed that the
distribution in uncoiling velocities and lifetimes is rather
broad, which led to the speculation that (part of) the
variation in these quantities was caused by diﬀering local
interactions at the numerous sites at which uncoiling took
place. We thus envisaged that conﬁning the uncoiling to a
unique site on the DNA might narrow the distribution
of uncoiling velocities, which would enable the accurate
Figure 1. Binding of the TFO–TPT construct and site-speciﬁc cleavage by TopIB. (a) A triple helix-forming oligonucleotide (red), covalently linked
to a topotecan (TPT) molecule binds in the major groove of DNA (blue). (b) Synthetic route for the preparation of 10-(6-aminohexyloxy)-topotecan
NTPT (referred to as TPT) and 10-(6-aminohexyloxy)-camptothecin NCPT (referred to as CPT). The chemical structure of the conjugates TFO–TPT
and TFO–CPT. (c) The target site on the duplex is underlined and the topoisomerase I-mediated DNA cleavage site is indicated by an arrow.
M, 5-methyl-20-deoxycytidine; P, 5-propynyl-20-deoxyuridine. (d) PAGE analysis of triple helix formation: the duplex target RY
  ([RY
 ]=20nM),
radiolabeled at the 50 end of the pyrimidine strand Y
 , is incubated at 378C in 50mM HEPES pH=7.2, 100mM NaCl, 10mM MgCl2 in the
presence of decreasing concentrations of: TFOs (1, 0.5, 0.3, 0.2 and 0.1mM), TFO–TPT (2, 1, 0.8, 0.5 and 0.1mM) and TFO–CPT (5, 2, 1 and
0.5mM). Aliquots were removed after 2h of incubation at 378C and analyzed on a 15% nondenaturating acrylamide gel. (e) A radiolabeled
324-bp DNA fragment containing the duplex target (lane 1) was incubated at 378C and pH 7.2 (28) in the presence of topoisomerase (lane 2) and of
the TFO at 5mM (lane 3), CPT at 10mM (lane 4), TFO–CPT at 5mM (lane 5), TPT at 10mM (lane 6) and TFO–TPT at 5mM (lane 7). Adenine/
guanine-speciﬁc Maxam–Gilbert chemical cleavage reactions were used as markers (G+A). The position of the cleavage site of the conjugates is
indicated by an arrow. The region corresponding to the triplex site is indicated (TFO), as the orientation.
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parameters such as force and torque. In this way, our
experiments allow us to determine whether sequence plays
a dominant role in the dynamics of DNA uncoiling, which
may help streamline the eﬀorts currently underway to
chemically improve the drugs.
MATERIALS AND METHODS
Synthesis ofcamptothecin and topotecan analogs
Mass determination was accomplished by electrospray
ionization on a Q-STAR pulsar I (Appleura) and HPLC
puriﬁcations were performed upon Agilent 1100 using a
Xterra reverse phase C18 column (4.6 50mm, 2.5mm).
1H NMR were recorded in Me2SO-d6 on a Varian spectro-
meter (300mHz). All the drugs were dissolved in Me2SO.
10-hydroxycamptothecin was purchased from Sigma and
topotecan from Molekula.
Synthesis of10-(6-aminohexyloxy)-topotecan NTPT
(2):10-(6-Boc-aminohexyloxy)-topotecan
To a solution of 5mg (11mmol) topotecan hydrochloride
in dry DMF (50ml) was added diisopropylethylamine
(4ml; 44mmol) and 6-(Boc-amino)hexyl bromide (10ml;
44mmol). The mixture was stirred at 408C for 48h, and
then analyzed and puriﬁed by reverse phase HPLC using
linear acetonitrile gradient (0–90% CH3CN with 0.1% of
TFA) to aﬀord a yellow solid (2.4mg; 3.5mmol; yield:
39%). ES-MS: found: (M+H) 620.33, calculated: 620.32
(C34H44N4O7).
1H NMR (Me2SO-d6): d(p.p.m.)=0.87
(t, 3H, J=7.2Hz), 1.3–1.5 (m, 15H), 1.8–1.9 (m, 4H),
2.8–3 (m, 8H), 4.31 (t, 2H, J=6.4Hz), 4.7–4.8 (m, 2H),
5.30 (s, 2H), 5.43 (s, 2H), 6.47 (br, 0.8H), 7.31 (s, 1H),
7.89–7.92 (d, 1H, J=9.5Hz), 8.31–8.35 (d, 1H,
J=9.5Hz), 8.96 (s, 1H).
10-(6-aminohexyloxy)-topotecan
The Boc-protected topotecan (2.8mg; 4.6mmol) was
dissolved in CHCl3/TFA 1:1 and stirred at room
temperature for 20min (0.5ml). The solvent was removed
and the resulting product was puriﬁed by reverse phase
HPLC using linear acetonitrile gradient (0–90% CH3CN
with 0.1% of TFA) to aﬀord a yellow solid (8.7mg;
1.73mmol; yield: 88%). ES-MS: found: (M+H) 520.27;
calculated: 520.27 (C29H36N4O5).
1H NMR (Me2SO-d6):
d(p.p.m.)=0.88(t, 3H, J=7.4Hz), 1.36–1.60 (m, 6H),
1.8–1.9 (m, 4H), 2.7–2.9 (m, 8H), 4.30 (t, 2H, J=6.4Hz),
4.7–4.8 (m, 2H) 5.30 (s, 2H), 5.42 (s, 2H), 6.50 (br, 1H),
7.32 (s, 1H), 7.68 (br, 2H), 7.89–7.92 (d, 1H, J=9.5Hz),
8.33–8.36 (d, 1H, J=9.5Hz), 8.96 (s, 1H). See Figure 1b
for the detailed structure of this molecule.
Synthesis of10-(6-aminohexyloxy)-camptothecin NCPT
(4):10-(6-Boc-aminohexyloxy)-camptothecin
To a solution of 10mg (27mmol) 10-hydroxycamptothecin
in dry acetone (10ml) was added anhydrous potassium
carbonate (4.5mg; 32mmol) and 6-(Boc-amino)hexyl
bromide (11.3mg; 30mmol). The mixture was stirred at
reﬂux for 18h. The reaction mixture was ﬁltered and the
solvent removed. The resulting solid was analyzed and
puriﬁed by reverse phase HPLC using linear acetonitrile
gradient (0–90% CH3CN with 0.1% of TFA). This
aﬀorded a yellow solid (9.5mg; 1.69mmol; yield: 63%).
ES-MS: found: (M+H) 563.62 Calculated: 563.64
(C31H37N3O7).
1H NMR (Me2SO-d6): d(p.p.m.)=0.87
(t, 3H, J=7.3Hz), 1.3–1.6 (m, 15H), 1.79–2.07 (m, 4H),
2.72–2.83 (m, 2H), 4.13 (t, 2H, J=6.6Hz), 5.27 (s, 2H),
5.41 (s, 2H), 6.47 (s, 1H), 6.75 (m, 1H), 7.28 (s, 1H),
7.48–7.54 (m, 1H), 8.06 (d, 1H, J=9.7Hz), 8.52 (s, 1H).
10-(6-aminohexyloxy)-camptothecin
The Boc-protected camptothecin (8mg; 1.73mmol) was
dissolved in CHCl3/TFA 1:1 (1ml) and stirred at room
temperature for 2h. The solvent was removed and the
resulting product was puriﬁed by reverse phase HPLC
using linear acetonitrile gradient (0–90% CH3CN with
0.1% of TFA) to aﬀord a yellow/orange solid (8.7mg;
1.73mmol; yield: 90%). ES-MS: found: (M+H) 463.52;
calculated: 463.53 (C26H29N3O5).
1H NMR (Me2SO-d6):
d(p.p.m.)=0.88(t, 3H, J=7.3Hz), 1.4–1.65 (m, 6H),
1.79–2.26 (m, 4H), 2.71–2.83 (m, 2H), 4.15 (t, 2H,
J=6.7Hz), 5.27 (s, 2H), 5.43 (s, 2H), 6.40 (s, 1H), 7.28
(s, 1H), 7.48–7.54 (m, 1H), 7.61 (m, 2H), 8.05 (d, 1H,
J=9.7Hz), 8.51 (s, 1H). See Figure 1b for the detailed
structure of this molecule.
General procedure forconjugation to theTFOs
Oligonucleotide TFO (sequence reported in Figure 1c)
was purchased from Eurogentec and puriﬁed using
quick spin columns and sephadex G-25 ﬁne (Boehringer,
Mannheim). Concentrations were determined spectro-
photometrically at 258C using molar extinction coeﬃ-
cients at 260nm calculated from a nearest-neighbor
model. The target DNA sequence is underlined in
Figure 1c.
After precipitation as hexadecyltrimethylammonium
salt 300mg (58mmol) of 30-phosphorylated oligonucleotide
(TFO) were dissolved in 45ml of dry Me2SO. Solutions of
4-dimethylaminopyridine [5mg (40mmol) in 30mlo f
Me2SO], dipyridyl disulﬁde (6.6mg in 30mlo fM e 2SO,
30mmol) and triphenylphospine (8mg in 30mlo fM e 2SO,
30mmol) were added. After 15min of incubation at room
temperature, the activated oligonucleotide was precipi-
tated with 2% LiClO4 in acetone, rinsed with acetone and
dissolved in a solution of 30mlo fM e 2SO/water 8:2 of
the amino-derivative (0.5mmol). After 2h of incubation,
the oligonucleotide conjugate was precipitated with 2%
LiClO4 in acetone, rinsed with acetone and puriﬁed by
reverse phase HPLC using linear acetonitrile gradient
[0–80% CH3CN in 0.2M (NH4)OAc]. TFO–TPT (yield
74%): ES-MS: found: (M+H) 5646.3 calculated: 5646.2.
HPLC retention time: 12.9min. TFO–CPT (yield 69%):
ES-MS: found: (M+H) 5589.0 calculated: 5590.2. HPLC
retention time: 12.4min.
TFO–TPT and TFO–CPT binding to dsDNA
We show that the TFO–TPT and TFO–CPT conjugates
bind to dsDNA and form a triple helix at pH 7.2 and
378C, 100mM NaCl and 10mM MgCl2. The binding is
Nucleic Acids Research, 2008, Vol. 36, No. 7 2303observed by a decrease in the mobility on a nondenaturing
polyacrylamide gel with increasing conjugate concentra-
tions (Figure 1d). The radiolabeled oligopyrimidine strand
of the duplex and the radiolabeled duplex were used as
markers. The experimental procedure is described in
ref. 28. Subsequent sequence-speciﬁc DNA cleavage by
the conjugates is described in the Results section and
Figure 1e.
Single-molecule experimental configuration and
bufferconditions
Our experimental design, the magnetic tweezers, consists
of a pair of magnets mounted above a ﬂow cell of
two glass slides with paraﬁlm spacing (30,31). A linear
continuous single dsDNA molecule with a length
of  19.2kb is tethered at its biochemically modiﬁed
ends between a paramagnetic bead and the bottom
glass slide using standard streptavidin-biotin (bead) and
digoxygenin-anti-digoxigenin (surface) interactions. The
central portion of DNA contains part of a Supercos1
plasmid (Stratagene), while the ends are 1238-bp stretches
of pbluescriptIISK+ plasmid (Stratagene) obtained using
a PCR reaction with biotinylated or digoxigenin-labeled
nucleotides. Twisting the magnets about their center axis
twists the DNA molecule, while translating the magnets in
the vertical direction modulates the stretching force F on
the DNA.
To perform single-molecule experiments on DNA
molecules containing a TFO, the triple helix was ﬁrst
preformed inside the ﬂow cell by ﬂushing in a buﬀer
containing 50mM Tris–HCl (pH 7.2), 10mM MgCl2,
60mM KCl, 0.5mM DTT, 200mg/ml BSA, 0.1mM
EDTA and 10mM TFO. The TFO was incubated for
90min at room temperature. Experiments were performed
in a buﬀer containing 50mM Tris–HCl (pH 7.2), 10mM
MgCl2, 60mM KCl, 0.5mM DTT, 200mg/ml BSA, 0.1%
Tween. Under these conditions, the only TPT molecules
present in the ﬂow cell are those that are conjugated to the
TFO. As we observe TPT-mediated slow supercoil
removal in these buﬀer conditions, we can be sure that
the triple helix remains formed during the course of the
experiments.
RESULTS
Synthesis and bindingof conjugates
The synthesis of the TFO conjugate of topotecan
(TFO–TPT; Figure 1a) required the preparation of
10-(6-aminohexyloxy)-topotecan (NTPT). In the remain-
der of the text, NTPT and NCPT are referred to as TPT
and CPT, respectively. The synthesis was carried out as
outlined in Figure 1b (see also Materials and Methods
section). The substitution of the phenolic OH was a
critical step and mild conditions (408C for 48h) were used
in order to avoid degradation of topotecan. Deprotection
in TFA yielded the TPT in 35% yield. For comparison the
same linker arm (6-aminohexyloxy) was attached to 10-
hydrocamptothecin following standard procedures (CPT:
84% yield). The two amino-derivatives (2 and 4) were
attached to the 30 phosphate group of the TFO as
described to obtain conjugates TFO–TPT and TFO–CPT.
Triplex formation by the conjugates was attested by
PAGE (Figure 1d, Materials and Methods section). As
expected, the presence of the drug destabilizes triplex
formation, however the triple helix is still strongly formed
at 378C in the presence of 10mM MgCl2 (C50=0.28, 0.75,
0.83mM for TFO, TFO–TPT and TFO–CPT, respec-
tively). In vitro cleavage experiments conﬁrm that the
conjugate induced TopIB-mediated DNA cleavage at a
single site only (Figure 1e), located at the 30 end of the
triplex site where the drug is positioned by triplex
formation (Figure 1c). We thus conclude that TFO–TPT
binds to dsDNA and induces TopIB-mediated DNA
cleavage at a predeﬁned position. The cleavage obtained in
the presence of TFO–CPT is seven times stronger than the
one obtained in the presence of TFO–TPT. This diﬀerence
is presumably due to a better ﬁt by the TFO ligand of the
CPT derivative in the ternary complex than the TPT one.
The TFO does notinfluence the mechanical properties
of theDNA
Our experimental conﬁguration, the magnetic tweezers, is
described elsewhere (30,31) and in brief consists of
monitoring the length of a tethered DNA molecule in a
ﬂow cell above which a pair of magnets is mounted (see
Materials and Methods section). Upon twisting the
molecule via magnet rotation, plectonemic supercoils
form (Figure 2a), causing the height of the bead above
the surface to decrease. When TopIB (blue C-shaped
structures) is added in combination with the TFO–TPT
(TFO shown in red, TPT in black), the plectonemes will
be removed (Figure 2b). This can occur either in a TPT-
dependent manner, in which case the DNA sequence
at which the uncoiling occurs is known, or in a TPT-
independent manner, which occurs at an unknown
sequence.
We performed several control experiments to ensure
that the binding of the TFO–TPT did not inﬂuence
the mechanical properties of the DNA molecule. As this
study examines the enzymatic relaxation of plectonemic
supercoils in the presence of a TFO, we ﬁrst probed
the inﬂuence of TFO on the mechanical coiling and the
formation of plectonemic supercoils. To this end, we
applied twist to the DNA molecule by rotating the
magnets, either in the presence or absence of a bound
triple helix. We then tested whether plectonemic supercoils
formed at the same degree of twist and whether the
supercoils that formed were of similar dimensions.
Rotating the magnets about their axis in the direction of
the natural helicity of the DNA induces overwinding of
the DNA molecule that will lead to buckling of the DNA
and the formation of positive plectonemic supercoils
[Figure 3a and (32)]. Rotating in the opposite direction
leads to underwinding and the formation of negative
supercoils in the DNA. Figure 3b plots the DNA
extension as a function of the number of magnet rotations.
At low stretching force (F smaller than  0.5pN, depend-
ing on buﬀer conditions), the DNA’s response to twist
is symmetrical for positive and negative supercoils and
2304 Nucleic Acids Research, 2008, Vol. 36, No. 7is identical for DNA without TFO bound (red data
points) and for DNA with TFO bound (blue data points).
Error bars denote the standard deviation of the bead
ﬂuctuations.
We also asked whether a bound TFO would inﬂuence
the swivelling of a supercoiled DNA molecule after
cleavage by an enzyme. Torque stored in the supercoiled
DNA will dissipate through the nick upon cleavage by
topoisomerase or a nicking enzyme. As a result, the DNA
will start to spin (green arrow in Figure 3c), plectonemic
supercoils are removed and the bead will move upwards.
The dynamics of DNA extension following cleavage by a
nicking enzyme has previously been quantitatively studied
and modeled (33), allowing us to rapidly assess the
inﬂuence of the TFO on this process. The nicking
enzyme and the TopIB used in subsequent experiments
cut the DNA at comparable distances from the 30-end of
the triplex (5bp versus 4bp, respectively). The DNA
extension trajectory in time after cleavage by a nicking
enzyme (at time t=0s) is plotted in Figure 3d (black dots
are samplings of the bead height at 60Hz). The red solid
line in Figure 3d is the prediction of a quasi-static model
for the stretching dynamics of DNA that takes into
account the constant stretching force pulling at the DNA,
the Stokes drag on the bead as it moves through the water,
and the entropic cost for extending a torsionally relaxed
worm-like chain such as DNA (33). The DNA extension
saturates at the equilibrium extension, which is a function
of F, of the crystallographic length of the DNA, and of the
persistence length of DNA, which we have independently
measured to be 53 2nm, in agreement with literature
(30). In the presence of TFO and a nicking enzyme, the
DNA extension trajectory in time is equally well described
by the model (Figure 3e and f). We thus conclude that the
presence of the TFO does not inﬂuence the quasi-static
mechanical properties of the DNA, or the uncoiling
dynamics upon enzymatic cleavage at a locus close to
the TFO.
Drug-mediated slow uncoiling and lifetime of the
covalentcomplex
Previous experiments have shown that in the presence of
TopIB, the plectonemes in a mechanically supercoiled
DNA molecule are enzymatically removed at a low rate if
the uncoiling is mediated by TPT (19). In summary, for
the removal of positive supercoils this rate was typically
found to be roughly 20 times lower in comparison to the
rate of non-TPT-mediated supercoil removal and is only
observed in the presence of a catalytically active human
TopIB. Furthermore, the rate of DNA religation is
decreased  400-fold (19). Thus, slow supercoil removal
constitutes a signature for TPT-mediated uncoiling and
can be used to measure the lifetime of the covalent
complex. Here we extend these measurements by investi-
gating the eﬀect of DNA sequence using the TFO–TPT
construct. With a bound TFO–TPT and in the presence of
TopIB, slow supercoil removal can be observed (red data
points in Figure 4a), similar to experiments with free TPT
(19). We note that with free TPT in solution as well as with
the TFO–TPT construct, most uncoiling events are not
TPT-mediated. However, with the TFO–TPT construct,
the relative frequency of TPT-mediated uncoiling events is
even lower (less than  10%), in agreement with the
restriction that this experimental design imposes on the
number of available DNA loci for TPT-mediated uncoil-
ing. The time duration of slow supercoil removal, Dt, was
measured and the outcomes are displayed in a histogram,
both for the TFO–TPT construct (sequence-speciﬁc
uncoiling, Figure 4b, <Dt>=115s) and free TPT in
Triple helix forming 
oligonucleotide
Topotecan
molecule
Topotecan-mediated uncoiling
by Top1B occurs only at sequence
determined by triple helix forming
oligonucleotide
Top1B free in solution
(a)
(b)
Figure 2. Experimental strategy to detect sequence-speciﬁc uncoiling by
TopIB at the single-molecule level. (a) A supercoiled double-stranded
and continuous DNA molecule (blue) is tethered between a magnetic
bead (gray sphere) and a glass surface. The TFO (red), connected to the
TPT (black) binds in a sequence-speciﬁc manner to the DNA molecule.
TopIB enzyme molecules (blue C-shaped structures) diﬀuse freely in
buﬀer solution. (b) TopIB can only remove DNA supercoils in a drug-
dependent manner at a site on the DNA that is dictated by the
sequence-speciﬁc binding of the TFO–TPT.
Nucleic Acids Research, 2008, Vol. 36, No. 7 2305Nicking enzyme removes
DNA supercoils and bead
moves up
Triple helix forming 
oligonucleotide
Nicking enzyme removes 
DNA supercoils and bead 
moves up
(+) supercoils
(−) supercoils
(+) (−)
N S
(a)( b)
(c)( d)
(e)( f)
Figure 3. The presence of the TFO does not inﬂuence quasi-static mechanical properties of DNA. (a) Using the magnetic tweezers, positive (+) or
negative (–) supercoils can be readily introduced in the DNA molecule by either twisting the magnets along with (green arrow) or against (red arrow)
the natural helicity of the DNA. (b) Under the appropriate conditions of stretching force and buﬀer, the response of the DNA molecule to twisting is
symmetrical: both (+) and (–) supercoils cause the DNA extension to decrease in an equal manner, as plectonemic supercoils form. (c) A positively
supercoiled molecule will relax, when cleaved by a nicking enzyme. Consequently, the DNA extension will increase in time. (d) The dynamics of the
uncoiling is in thermal equilibrium, and is well-predicted by a model that is described in ref. 33. (e) Cleavage of a supercoiled DNA molecule, in the
presence of a bound TFO construct. The sequence of the TFO is chosen such that cleavage occurs at a distance of 5bp from the 30-end of the TFO.
(f) The dynamics of supercoil removal after cleavage with a nicking enzyme in the presence of TFO is well described by the quasi-static model,
similar to (d).
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<Dt>=124s). It is apparent from Figure 4b and c that
the distributions do not diﬀer signiﬁcantly. Earlier
biochemical studies have shown that camptothecin stabi-
lizes the covalent TopIB–DNA intermediate at a number
of diﬀerent sites on the DNA to diﬀerent degree (12,14).
We thus expected that in the context of single-molecule
measurements, the broadness of the Dt-distribution for
free TPT in solution (Figure. 4c) might be caused by the
heterogeneity in the degree to which diﬀerent sites on the
DNA are stabilized. However, we ﬁnd that the broadness
of the Dt-distribution for a unique DNA sequence, i.e. in
the TFO–TPT measurement, is roughly as broad as the
Dt-distribution for multiple sites, i.e. in the free TPT
measurement. We therefore conclude that the variation in
Dt is not caused by variation in DNA sequence at which
uncoiling occurs. There is, however, one relevant caveat in
the measurement of Dt, which is that this number may
constitute a lower bound (19). This is because the
transition from slow uncoiling to fast uncoiling, which is
used as the criterion for the time up to which slow
supercoiling persists, can be explained in two diﬀerent
ways. First, this transition can be caused by TPT exiting
the covalent complex, in which case the measurement of
Dt is a correct measure of the lifetime of the covalent
complex [religation is fast compared to Dt, (19)]. The
second explanation is that during slow TPT-mediated
supercoil removal by a ﬁrst TopIB, a second, independent
TopIB cleaves the DNA at another site on the DNA in a
TPT-independent manner, giving rise to fast supercoil
removal. In this case, Dt is a measure for the time between
independent cleavage events by diﬀerent TopIBs, and
represents a lower bound for the lifetime of the covalent
complex. In principle, varying the TopIB concentration in
the ﬂow cell ought to exclude the second explanation. We
have varied the concentration by a factor of 2, which is the
largest concentration range experimentally feasible (6) and
have seen no eﬀect on the Dt distribution (19). However,
we cannot be fully conﬁdent that the TopIB concentration
in the bulk solution changes as expected given the large
surface-to-volume ratio of the ﬂow cell and the tendency
of TopIB to bind to the negatively charged polyglutamic
acid used to passivate the ﬂow cell surfaces. We can
nonetheless conclude that restricting the formation of a
TPT-stabilized covalent complex to a speciﬁc sequence
does not dramatically alter its lifetime in comparison to
the situation in which the complex is allowed to form at an
ensemble of sites on the DNA.
Measurementof theuncoiling velocities of positive
andnegative supercoils
To quantify the rate of drug-mediated supercoil removal
by TopIB at a single DNA sequence, we measured
the distribution of uncoiling velocities during supercoil
Slow topotecan-mediated 
and site-specific uncoiling 
of the DNA by Top1B 
Mechanical 
recoiling 
of the DNA
Free topotecan
in solution
Topotecan-TFO
bound to DNA site-specifically
(a)
(b)
(c)
Figure 4. Lifetime of the covalent TopIB–DNA complex. (a) The DNA
molecule is mechanically coiled by twisting the magnets, leading to a
decrease in DNA extension (green lines). In this trace, positive
supercoils are immediately removed by TopIB in a TPT-dependent
fashion, with TPT bound to the TFO. Supercoil removal manifests
itself as a slow increase in DNA extension (red dots). The total time
duration of slow continuous supercoil removal, <Dt>, is measured
for a number of uncoiling events for both sequence-speciﬁc uncoiling
using the TFO–TPT construct (b, red histogram, n=20) and for
nonsequence-speciﬁc uncoiling using free TopIB in solution (c, blue
histogram, n=122). The distributions have similar widths.
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<v>=0.5 0.1mm/s) and TFO–CPT (Figure 5b,
<v>=0.4 0.1mm/s) constructs. These were compared
to the measurements in the presence of free TPT
(Figure 5c, <v>=0.3 0.1mm/s). Here, a velocity of
2.1mm/s was used as a cutoﬀ to deﬁne TPT-mediated
events, and all errors indicated are standard deviations.
We also measured the asymmetry in uncoiling rates
!=!+–!–(19) in the presence of a bound TFO–TPT
(Figure 5d,<!>=–8 6Hz) and for free TPT
(Figure 5e, <!>=–8 5Hz). What is apparent from
these histograms is that the distributions are roughly
equally broad in the case of sequence-speciﬁc uncoiling
in comparison to sequence-independent uncoiling.
One might expect that the local microscopic environment,
i.e. the molecular interactions between the drugs, the
TopIB and the DNA would be of such importance that
the eﬀect of sequence would manifest itself in our sensitive
single-molecule measurements. In such a case, we would
speciﬁcally have predicted that conﬁning the drug-
mediated uncoiling to a unique site would lead to a
narrowing of the distribution of uncoiling velocities. This
prediction was not borne out in our measurements and we
conclude that sequence does not play a dominating role in
the velocity of drug-mediated DNA uncoiling. Thus, while
our single-molecule experiments can sensitively detect
the altered dynamics of supercoil removal as a result of
subtle eﬀects such as a change in the helicity of uncoiling,
ω 
Topotecan free 
in solution
Topotecan-oligonucleotide 
bound to DNA site-specifically
(a)
(b)
(c)
(d)
(e)
Figure 5. Instantaneous uncoiling velocity in the presence of TPT. Uncoiling velocities in the presence of the camptothecins. (a), (b) and (c) show
histograms of instantaneous uncoiling velocities of TFO–TPT ((a), n=51, red histogram), TFO-CPT ((b), n=110, green histogram) and free TPT in
solution (C, n=122, blue histogram). Histograms shown in (a), (b) and (c) are all similar in their means and width. (d) histogram of the asymmetry
in uncoiling velocities of the removal of negative and positive supercoils, in the presence of TFO–TPT (n=17, red histogram). D! is a measure for
the diﬀerential in uncoiling rates: D!=!+–!–, where !+ is the uncoiling rate of positive supercoils and !– is the uncoiling rate of negative
supercoils. (e) Histogram of the asymmetry in uncoiling velocities of the removal of negative and positive supercoils in the presence of free TPT in
solution (n=17, blue histogram). Histograms shown in (d) and (e) are similar in their means and width.
2308 Nucleic Acids Research, 2008, Vol. 36, No. 7they reveal that the role of DNA sequence in the drug-
mediated TopIB dynamics is in comparison relatively
minor.
DISCUSSION
We have experimentally demonstrated topotecan- and
camptothecin-mediated slow supercoil removal by human
topoisomerase IB restricted to a speciﬁc site on the DNA.
Our main conclusion is that the dynamics of slow
uncoiling observed at a single site is indistinguishable
from the slow uncoiling we observe on DNA molecules
where multiple sites are available for drug binding. The
experimental observables that showed no diﬀerence were
the instantaneous rate of positive and negative supercoil
removal, as well as the lifetime of the drug-stabilized
covalent TopIB–DNA complex. In the context of these
measurements, we raise a number of points for discussion.
First, the lifetime of the covalent complex in the
presence of drug is about 2min, both for sequence-speciﬁc
and nonsequence-speciﬁc uncoiling (19). The observation
that these two quantities are identical for all practical
purposes indicates that the measurement of the lifetime for
free TPT could not have been overestimated due to a
potential limitation to distinguish two subsequent and
independent TopIB enzymes uncoiling in the presence of
drug at two diﬀerent sites on the DNA. In such a scenario,
a recorded event of long uncoiling could in reality consist
of two events that are somewhat shorter in duration, but
overlap in time.
Second, it may still be possible that ‘the same’ TPT
molecule enters and exits the TopIB–DNA complex on a
time scale that is faster than our time resolution. However,
we note that this is not a particularly relevant caveat from
a biological point of view, as such fast dynamics still lead
to slow DNA uncoiling, which is what the cell and its
DNA processing apparatus, and in particular the replica-
tion fork, has to confront.
Third, our data suggest that DNA sequence does not
inﬂuence the uncoiling rate and the lifetime of the drug-
stabilized covalent complex. It might have been expected
that the exact chemical structure at the swivel point of the
TopIB would inﬂuence the swivel rate. Similarly, it might
have been expected that the interactions between the
TopIB, the DNA and TPT would have an eﬀect on
the binding strength of TPT inside the enzyme cavity.
Both of these speculations are not borne out by our
measurements. Rather, the broad distributions that our
single-molecule measurements reveal may have to be
attributed to stochastic variations in the binding of the
TPT into the pocket formed by the TopIB and the nicked
DNA, stochastic variations in the manner that TopIB
encircles the DNA, or, in the case of the lifetimes of the
TPT complex, variable breathing modes of either the
TopIB or the DNA molecule itself.
The outcome of our dynamical experiments combined
with the relative sequence independence of DNA cleavage
(25) implies that sequence may not play an important
role in considerations of drug eﬃcacy. Particularly
if drug targeting proceeds via TFOs, the observed
sequence-independent dynamics suggest that such con-
jugates can be used as tools to direct the action of
camptothecin to a speciﬁc site (e.g. on a speciﬁc gene in the
human genome) without altering the poisoning features of
the drug. Our ﬁndings have an impact on the process
of designing improved camptothecins. Chemical modiﬁca-
tion of the TopIB (34) or camptothecins (35) appear to
aﬀect the TopIB reaction kinetics to a large degree, but
our data suggest that the DNA does not need to be taken
into account in the design process. This may pose a
potential simpliﬁcation in the strategy to target DNA
sequences speciﬁc to certain cancers, since the overall
strategy need not be adapted on a case-by-base basis.
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